Discovery & Characterization of a Selective, Pure Antagonist of TNFR1

• Introducing de novo designed miniproteins as a next generation therapeutic modality
• Highlighting the application to antagonism of TNFR1
• Showcasing differentiation against existing therapies

Speakers:

Phil Brandish

Chief Scientific Officer

AI Proteins